SLXP News 137.38 10/17/2014 05:40:54 Salix Pharmaceuticals (

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Salix Pharmaceuticals (SLXP) 137.38 $SLXP


AbbVie sours on $55B Shire deal after tax changes
By The Associated Press - AP - Thu Oct 16, 8:59AM CDT
AbbVie's board is telling shareholders to vote against its own $55 billion takeover bid for the Irish drugmaker Shire after the U.S. made reincorporating overseas a less lucrative tax maneuver.
MDT: 61.81 (-0.44), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96)

AbbVie Board To Shareholders: Vote No On Shire Buy
at Investor's Business Daily - Thu Oct 16, 12:22AM CDT
AbbVie (ABBV) late Wednesday said that its board of directors recommendation that shareholders reject a planned $55 billion buy of Shire Pharmaceuticals. The board citing new Treasury rules issued Sept. 22 making tax inversion deals less attractive....
AGN: 178.00 (+0.41), ACT: 222.07 (+4.83), MDT: 61.81 (-0.44), COV: 85.50 (-0.36), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96), ABBV: 52.90 (-1.73)

Shire Falls, AbbVie Questioned On Buyout Backtrack
at Investor's Business Daily - Wed Oct 15, 12:11PM CDT
Shares of specialty drugmaker Shire plummeted 23% on the stock market today after word got out late Tuesday that big pharma AbbVie is reconsidering its $55 billion buyout of the company. Shire (SHPG) confirmed the reports Wednesday morning with a...
ABT: 39.99 (-0.02), AZN: 67.56 (-0.85), PFE: 27.70 (-0.49), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96), MYL: 48.77 (+1.39), ABBV: 52.90 (-1.73)

Stocks Dive, Then Pare Losses; Shire, Expedia, KeyCorp Crumble
at Investor's Business Daily - Wed Oct 15, 9:37AM CDT
Stocks shaved early losses but remained down hard Wednesday as weak economic data hammered away at investor confidence. The S&P 500 showed a 1.7% loss, up from a more than 2% dive in early trade. The Dow Jones industrial average recovered to a 1%...
NFLX: 361.70 (-86.89), EBAY: 47.88 (-2.36), AXP: 80.24 (-0.69), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96), TRIP: 79.52 (+0.63), EXPE: 75.08 (+0.98), ABBV: 52.90 (-1.73), KEY: 12.19 (+0.05), INTC: 30.85 (-0.42)

After Yesterday's Decline of 1.25%, Salix Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 14, 4:03PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $129.91 to a high of $137.99. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $135.09 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SLXP: 137.38 (+4.96)

IBD 50: Medical, Internet Companies Top Q3 Estimates
at Investor's Business Daily - Mon Oct 13, 6:15PM CDT
Health care and Internet companies are expected to have some of the strongest third-quarter profit gains in the IBD 50. The consensus analyst estimates for medical leaders Gilead Sciences (GILD) and Lannett (LCI) exceed 200% growth. The June-quarter...
AMBA: 38.76 (+0.16), BIIB: 302.74 (-2.95), ACT: 222.07 (+4.83), VIPS: 189.33 (+3.65), YY: 76.37 (+3.97), SWKS: 51.53 (+1.93), FB: 72.63 (-0.58), AKRX: 35.80 (+0.85), KSU: 116.41 (+0.84), SLXP: 137.38 (+4.96), ATHM: 46.51 (+1.39), LCI: 41.66 (+1.36), ABC: 75.02 (-1.00), GILD: 96.88 (+0.72), AVGO: 75.60 (+3.05)

Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire
PR Newswire - Mon Oct 13, 7:30AM CDT
Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Arrowhead Research Corp. (NASDAQ: ARWR), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), HCA Holdings, Inc. (NYSE: HCA) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7111-100free.
HCA: 68.23 (+3.39), BIIB: 302.74 (-2.95), ARWR: 7.02 (+0.55), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96)

Salix Pharmaceuticals Partnering 2009 Industry Shares, Size, Trend, Analysis, and Forecasts to 2014 by Researchmoz
PRWeb - Sat Oct 11, 11:30PM CDT
The Partnering Agreements with Salix Pharmaceuticals 2009-2014 report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.
SLXP: 137.38 (+4.96)

Allergan Raises Outlook amidst Valeant Takeover Attempts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:20PM CDT
Allergan Inc. (AGN) raised its third quarter 2014 and full year 2014 earnings guidance.
AGN: 178.00 (+0.41), ACT: 222.07 (+4.83), VRX: 118.54 (+4.20), SLXP: 137.38 (+4.96)

Salix's Rectal Foam Uceris Receives Final FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 5:30PM CDT
Salix Pharmaceuticals, Ltd. (SLXP) announced that the FDA has granted final approval for Uceris rectal foam for the induction of remission in patients with active mild to moderately distal ulcerative colitis.
AGN: 178.00 (+0.41), VRX: 118.54 (+4.20), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96)

Salix Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.08%
Comtex SmarTrend(R) - Thu Oct 09, 4:57PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $140.13 to a high of $146.57. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $141.81 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SLXP: 137.38 (+4.96)

Actavis plc and Valeant Pharmaceuticals Inc. Battle for Allergan Inc.: Who Wins?
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 2:52PM CDT
Healthcare companies have been completing merger and acquisitions this year at record pace to counter  ongoing patent cliff troubles, as well as political gridlock in the U.S. over corporate tax reform.  Activist investor Bill Ackman and his hedge...
DRTX: 23.60 (-0.03), AGN: 178.00 (+0.41), VRX: 118.54 (+4.20), ACT: 222.07 (+4.83), SLXP: 137.38 (+4.96)

Allergan Steeply Raises Guidance, Taunts Valeant
at Investor's Business Daily - Thu Oct 09, 10:56AM CDT
Specialty drugmaker Allergan raised its guidance Thursday and took the opportunity to say yet again that Valeant Pharmaceuticals' hostile bid for the company was too low. Allergan (AGN) stock nonetheless was flat in morning trading on the stock...
AGN: 178.00 (+0.41), ACT: 222.07 (+4.83), VRX: 118.54 (+4.20), SLXP: 137.38 (+4.96)

Salix Pharmaceuticals wins US FDA's approval for UCERIS 2mg rectal foam for mild-to-moderate distal ulcerative colitis
M2 - Thu Oct 09, 9:09AM CDT
Medical company Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Wednesday the receipt of the US Food and Drug Administration's (FDA) final approval for UCERIS (budesonide) 2mg rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC) extending up to 40cm from the anal verge.
SLXP: 137.38 (+4.96)

FDA Approves UCERIS(R) (Budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis
Business Wire - Wed Oct 08, 7:30AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) has granted final approval for UCERIS(R) (budesonide) rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC) extending up to 40cm from the anal verge. The foam is a rectally administered corticosteroid that overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon.
SLXP: 137.38 (+4.96)

Salix Pharmaceuticals Partnering 2009 - 2014, New Report Launched
M2 - Wed Oct 08, 7:05AM CDT
Market Research Reports, Inc. has announced the addition of "Salix Pharmaceuticals Partnering 2009-2014" research report to their website http://www.MarketResearchReports.com
SLXP: 137.38 (+4.96)

Salix, Actavis Among Big Cap Pharmas In Merger Mambo
at Investor's Business Daily - Tue Oct 07, 6:33PM CDT
A one-on-one tango has since turned into a full-on hoedown as several major pharmaceutical companies continue to change partners on the M&A floor, with Valeant Pharmaceuticals (VRX) and Pershing Square Capital Management reportedly upping their bid...
DRTX: 23.60 (-0.03), AGN: 178.00 (+0.41), ACT: 222.07 (+4.83), VRX: 118.54 (+4.20), GILD: 96.88 (+0.72), JAZZ: 150.26 (+3.95), SLXP: 137.38 (+4.96), ABBV: 52.90 (-1.73), BMY: 49.22 (+0.26)

Salix Pharmaceuticals
at Investor's Business Daily - Tue Oct 07, 5:59PM CDT
Salix Pharmaceuticals (SLXP), seen as a possible target for Actavis or Allergan, closed down 2.4%, but rose 1% late on the Valeant report.
SLXP: 137.38 (+4.96)

Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene
at Investor's Business Daily - Tue Oct 07, 5:33PM CDT
Actavis has made acquisitions to transform from generic-focused drugmaker into a bigger player in prescription drugs and now finds itself in an enviable position -- thriving, with its home base in Ireland. Expected to generate $15 billion in revenue...
DRTX: 23.60 (-0.03), AGN: 178.00 (+0.41), PRGO: 145.69 (-0.16), VRX: 118.54 (+4.20), ACT: 222.07 (+4.83), PFE: 27.70 (-0.49), SLXP: 137.38 (+4.96), MYL: 48.77 (+1.39), TEVA: 51.56 (+1.47)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 163

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 129

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 120

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 25

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 74

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

Surge in Gold Prices Reflects Political and Economic Tensions

Updated Category News Views 283

Gold Prices Reach New Heights Amid Political Turmoil Gold prices have reached unprecedented levels recently, reflecting a surge in safe-haven demand driven by rising political uncertainties in key regions like the U.S. and Japan. As concerns about potential economic instability grow, this precious metal has emerged as a popular choice for investors looking to protect...

Continue Reading
BlackSky Secures Navy Contract to Enhance Satellite Imaging

Updated Category News Views 222

Alright, here’s the scoop: BlackSky Technology Inc. just bagged a major contract with the U.S. Navy, and it’s all about beefing up their Gen-3 imaging satellites. Now, why does this matter? This initiative is a piece of the broader Project Overmatch—a military strategy designed to supercharge the Joint All Domain Command and Control (JADC2) mission. What’s at...

Continue Reading
Discover the Innovative FINGER GRIP for Enhanced Sports Performance

Updated Category News Views 217

Enhancing Sports with the Innovative FINGER GRIP In the dynamic world of sports, having the right equipment can make all the difference. An inventive mind from Pittsburgh has introduced an innovative product, the FINGER GRIP, aimed at elevating performance in games like pickleball and tennis. This new grip is revolutionizing how athletes interact with their paddles and...

Continue Reading
Updated Voting Shares of AB Volvo: Significant Changes

Updated Category News Views 215

Changes in AB Volvo's Voting Shares AB Volvo has recently undergone an important transformation affecting its voting shares. The conversion of 175,000 Series A shares into Series B shares is a key development for the company. This conversion stems from a provision accepted at the 2011 Annual General Meeting, allowing Series A shareholders to switch their shares to Series...

Continue Reading
Warner Bros. Discovery's Q4: Strong Revenue Growth & Future Plans

Updated Category News Views 324

Warner Bros. Discovery Reports Impressive Q4 Results In a recent financial assessment, Warner Bros. Discovery, Inc (NASDAQ: WBD) unveiled its latest quarterly performance, showcasing a fiscal fourth-quarter revenue of $10.03 billion. Although this represented a slight 1% ex-FX decline compared to the previous year, it was just shy of analysts' expectations of $10.19...

Continue Reading